(Q36454787)

English

The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

anti-retroviral agent

0 references

0 references

Rochelle P. Walensky

10

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

object named as

Jason R Andrews

1

0 references

object named as

Elena Losina

8

0 references

2

object named as

Stephen D Lawn

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

4

object named as

Robin Wood

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Kenneth A. Freedberg

9

object named as

Kenneth A Freedberg

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

5

object named as

Farzad Noubary

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

author name string

Corina Rusu

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Melissa A Bender

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

C Robert Horsburgh

7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

language of work or name

0 references

publication date

1 May 2012

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

26

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

8

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

987-995

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Rapid molecular detection of tuberculosis and rifampin resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

The risk and timing of tuberculosis diagnosed in smear-negative TB suspects: a 12 month cohort study in Harare, Zimbabwe

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures -- a meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Scaling up antiretroviral therapy in South Africa: the impact of speed on survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Financing and cost-effectiveness analysis of public-private partnerships: provision of tuberculosis treatment in South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Delayed diagnosis of tuberculosis in patients with human immunodeficiency virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

28 June 2018

Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

21 September 2018

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

21 September 2018

CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

4 December 2018

The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22333751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands

1 reference

https://pubmed.ncbi.nlm.nih.gov/22333751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/QAD.0B013E3283522D47

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36454787&oldid=1632244779"